PETACH TIKVA, Israel, Nov. 13, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that the Company's CEO, Dr. Pnina Fishman, will present at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP)'s 2014 Annual Meeting. The meeting will take place in Boston, Massachusetts, from November 14-19, 2014.

Dr. Fishman's presentation, titled "Safety and Efficacy of CF101 in Rheumatoid Arthritis Patients: A Phase II Study," will be delivered on Sunday, November 16, at 5:15 pm Eastern Time during a session that will discuss novel therapies in rheumatoid arthritis.

During her presentation, Dr. Fishman will discuss Can-Fite's completed 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis (RA). The study entailed 2 arms; a placebo arm and a CF101 1 mg treated group, in which CF101 was administered orally twice-daily as a monotherapy for 12 weeks to patients with rheumatoid arthritis. In the study, patients treated with CF101 met all primary efficacy endpoints, showing statistically significant superiority over placebo in reducing signs and symptoms of RA as compared to the placebo.

"I am honored to present our Phase IIb rheumatoid arthritis data at the ACR/ARHP annual meeting," said Dr. Fishman. "Rheumatoid arthritis represents an unmet medical need, and novel approaches such as CF101 are needed. Based on the safety and efficacy data we have reported from clinical studies to date, we believe CF101 has the potential to significantly improve patient outcomes."

The ACR/ARHP Annual Meeting brings together nearly 15,000 domestic and international participants, including physicians, health professionals, and industry partners from over 100 countries. This six-day meeting will showcase cutting edge and timely topics in clinical and basic science of rheumatologic care, as well as the prevention, diagnosis, and treatment of rheumatic diseases and its comorbid conditions.

About Rheumatoid Arthritis

Rheumatoid arthritis is a chronic inflammatory disorder that typically affects the small joints in the hands and feet. Unlike the wear-and-tear damage of osteoarthritis, rheumatoid arthritis affects the lining of the joints, causing a painful swelling that can eventually result in bone erosion and joint deformity.

An autoimmune disorder, rheumatoid arthritis occurs when the immune system mistakenly attacks one's own body's tissues. In addition to causing joint problems, rheumatoid arthritis sometimes can affect other organs of the body such as the skin, eyes, lungs and blood vessels.

Although rheumatoid arthritis can occur at any age, it usually begins after age 40. The disorder is much more common in women than in men. Treatment focuses on controlling symptoms and preventing joint damage.

About CF101

CF101 is a small molecule orally bioavailable drug which binds with high affinity and selectivity to the adenosine A3 receptor (A3AR), which is known to be over-expressed in inflammatory cells. The correlation between A3AR expression levels prior to treatment and patients' response to CF101 suggests that the A3AR may be utilized a predictive biomarker to be analyzed prior to patients' treatment. CF101 is currently being developed for the treatment of rheumatoid arthritis and other inflammatory indications, including psoriasis, for which positive data from an interim analysis of an ongoing Phase II/III study was recently released by the Company.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company's CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite's liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information, please visit: www.can-fite.com

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite's filings with the SEC and in its periodic filings with the TASE.  In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control.  Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114

Argot Partners (Investors and Media)
Matthew Haines
matthew@argotpartners.com
646-681-8192

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/can-fite-ceo-dr-pnina-fishman-to-present-recently-released-positive-data-from-its-rheumatoid-arthritis-phase-iib-study-at-the-2014-american-college-of-rheumatology-annual-meeting-408720804.html

SOURCE Can-Fite BioPharma Ltd.